Deferoxamine free base| CAS# 70-51-9 | metal binder

MedKoo Cat#: 412110 | Name: Deferoxamine free base

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Deferoxamine is a bacterial siderophore produced by the Actinobacteria Streptomyces pilosus. It has medical applications as a chelating agent used to remove excess iron from the body. The mesylate salt of DFO-B is commercially available. It is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system. Deferoxamine acts by binding free iron in the bloodstream and enhancing its elimination in the urine.

Chemical Structure

Deferoxamine free base

CAS#70-51-9 (free base)

Theoretical Analysis

MedKoo Cat#: 412110

Name: Deferoxamine free base

CAS#: 70-51-9 (free base)

Chemical Formula: C25H48N6O8

Exact Mass: 560.3534

Molecular Weight: 560.69

Elemental Analysis: C, 53.55; H, 8.63; N, 14.99; O, 22.83

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 450.00	2 Weeks
50mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

70-51-9 (free base) 1950-39-6 (HCl) 138-14-7 (mesylate) 25442-95-9 (hydrate)

Synonym

Deferoxamine; Ba33112; Ba-33112; Ba 33112; Desferrioxamine B; Desferrioxamine; Deferoxamin; Desferin; Desferan; Desferex; Desferral; Desferrin

IUPAC/Chemical Name

1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetyl hydroxylamino)-6,11,17,22-tetraazaheptaeicosane

InChi Key

UBQYURCVBFRUQT-UHFFFAOYSA-N

InChi Code

InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)

SMILES Code

O=C(CCC(NCCCCCN(C(C)=O)O)=O)N(O)CCCCCNC(CCC(N(O)CCCCCN)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Deferoxamine is specifically used in iron overdose, hemochromatosis either due to multiple blood transfusions or an underlying genetic condition, and aluminum toxicity in people on dialysis.

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 560.69 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Lange MD, Abernathy J, Shoemaker CA, Zhang D, Kirby A, Peatman E, Beck BH. Proteome analysis of virulent Aeromonas hydrophila reveals the upregulation of iron acquisition systems in the presence of a xenosiderophore. FEMS Microbiol Lett. 2020 Oct 12:fnaa169. doi: 10.1093/femsle/fnaa169. Epub ahead of print. PMID: 33045069. 2: Inoue H, Hanawa N, Katsumata SI, Aizawa Y, Katsumata-Tsuboi R, Tanaka M, Takahashi N, Uehara M. Iron deficiency negatively regulates protein methylation via the downregulation of protein arginine methyltransferase. Heliyon. 2020 Oct 3;6(10):e05059. doi: 10.1016/j.heliyon.2020.e05059. PMID: 33033759; PMCID: PMC7533365. 3: Behroozian S, Svensson SL, Li LY, Davies JE. Broad-Spectrum Antimicrobial and Antibiofilm Activity of a Natural Clay Mineral from British Columbia, Canada. mBio. 2020 Oct 6;11(5):e02350-20. doi: 10.1128/mBio.02350-20. PMID: 33024043. 4: Yang J, Dong D, Luo X, Zhou J, Shang P, Zhang H. Iron Overload-Induced Osteocyte Apoptosis Stimulates Osteoclast Differentiation Through Increasing Osteocytic RANKL Production In Vitro. Calcif Tissue Int. 2020 Nov;107(5):499-509. doi: 10.1007/s00223-020-00735-x. Epub 2020 Sep 29. PMID: 32995951. 5: Li D, Jiang C, Mei G, Zhao Y, Chen L, Liu J, Tang Y, Gao C, Yao P. Quercetin Alleviates Ferroptosis of Pancreatic β Cells in Type 2 Diabetes. Nutrients. 2020 Sep 27;12(10):E2954. doi: 10.3390/nu12102954. PMID: 32992479. 6: Fan BY, Pang YL, Li WX, Zhao CX, Zhang Y, Wang X, Ning GZ, Kong XH, Liu C, Yao X, Feng SQ. Liproxstatin-1 is an effective inhibitor of oligodendrocyte ferroptosis induced by inhibition of glutathione peroxidase 4. Neural Regen Res. 2021 Mar;16(3):561-566. doi: 10.4103/1673-5374.293157. PMID: 32985488. 7: Kletkiewicz H, Klimiuk M, Woźniak A, Mila-Kierzenkowska C, Dokladny K, Rogalska J. How to Improve the Antioxidant Defense in Asphyxiated Newborns- Lessons from Animal Models. Antioxidants (Basel). 2020 Sep 21;9(9):E898. doi: 10.3390/antiox9090898. PMID: 32967335. 8: Kato I, Kasukabe T, Kumakura S. Menin‑MLL inhibitors induce ferroptosis and enhance the anti‑proliferative activity of auranofin in several types of cancer cells. Int J Oncol. 2020 Oct;57(4):1057-1071. doi: 10.3892/ijo.2020.5116. Epub 2020 Aug 28. PMID: 32945449. 9: Ohiomokhare S, Olaolorun F, Ladagu A, Olopade F, Howes MR, Okello E, Olopade J, Chazot PL. The Pathopharmacological Interplay between Vanadium and Iron in Parkinson's Disease Models. Int J Mol Sci. 2020 Sep 14;21(18):E6719. doi: 10.3390/ijms21186719. PMID: 32937783. 10: Dias Lopes NM, Marinello PC, Sanches LJ, da Silva Brito WA, Lovo-Martins MI, Pinge-Filho P, Luiz RC, Cecchini R, Cecchini AL. Patterns of cell death induced by metformin in human MCF-7 breast cancer cells. Pathol Res Pract. 2020 Sep 6;216(11):153199. doi: 10.1016/j.prp.2020.153199. Epub ahead of print. PMID: 32932214. 11: Farr AC, Xiong MP. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage. Mol Pharm. 2020 Oct 9. doi: 10.1021/acs.molpharmaceut.0c00474. Epub ahead of print. PMID: 32926630. 12: Goulas V, Kouraklis-Symeonidis A, Manousou K, Lazaris V, Pairas G, Katsaouni P, Verigou E, Labropoulou V, Pesli V, Kaiafas P, Papageorgiou U, Symeonidis A. A multicenter cross-sectional study of the quality of life and iron chelation treatment satisfaction of patients with transfusion-dependent β-thalassemia, in routine care settings in Western Greece. Qual Life Res. 2020 Sep 13. doi: 10.1007/s11136-020-02634-y. Epub ahead of print. PMID: 32920766. 13: Jung KH, Park JW, Lee JH, Lee EJ, Moon SH, Cho YS, Lee KH. 89Zr Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression. J Nucl Med. 2020 Sep 11:jnumed.120.250720. doi: 10.2967/jnumed.120.250720. Epub ahead of print. PMID: 32917780. 14: Yang RZ, Xu WN, Zheng HL, Zheng XF, Li B, Jiang LS, Jiang SD. Involvement of oxidative stress-induced annulus fibrosus cell and nucleus pulposus cell ferroptosis in intervertebral disc degeneration pathogenesis. J Cell Physiol. 2020 Sep 6. doi: 10.1002/jcp.30039. Epub ahead of print. PMID: 32892384. 15: Vlahakos VD, Marathias KP, Arkadopoulos N, Vlahakos DV. Hyperferritinemia in patients with COVID-19: An opportunity for iron chelation? Artif Organs. 2020 Sep 3. doi: 10.1111/aor.13812. Epub ahead of print. PMID: 32882061. 16: Abdul Y, Li W, Ward R, Abdelsaid M, Hafez S, Dong G, Jamil S, Wolf V, Johnson MH, Fagan SC, Ergul A. Deferoxamine Treatment Prevents Post-Stroke Vasoregression and Neurovascular Unit Remodeling Leading to Improved Functional Outcomes in Type 2 Male Diabetic Rats: Role of Endothelial Ferroptosis. Transl Stroke Res. 2020 Sep 1. doi: 10.1007/s12975-020-00844-7. Epub ahead of print. PMID: 32875455. 17: Takpradit C, Viprakasit V, Narkbunnam N, Vathana N, Phuakpet K, Pongtanakul B, Sanpakit K, Buaboonnam J. Using of deferasirox and deferoxamine in refractory iron overload thalassemia. Pediatr Int. 2020 Aug 27. doi: 10.1111/ped.14444. Epub ahead of print. PMID: 32856363. 18: Mukosera GT, Liu T, Manaen M, Zhu L, Power G, Schroeder H, Blood AB. Deferoxamine produces nitric oxide under ferricyanide oxidation, blood incubation, and UV-irradiation. Free Radic Biol Med. 2020 Aug 20;160:458-470. doi: 10.1016/j.freeradbiomed.2020.08.004. Epub ahead of print. PMID: 32828952. 19: Heirani-Tabasi A, Mirahmadi M, Mishan MA, Naderi-Meshkin H, Toosi S, Matin MM, Bidkhori HR, Bahrami AR. Comparison the effects of hypoxia-mimicking agents on migration-related signaling pathways in mesenchymal stem cells. Cell Tissue Bank. 2020 Aug 19. doi: 10.1007/s10561-020-09851-2. Epub ahead of print. PMID: 32815062. 20: Gazeri A, Aminzadeh A. Protective effects of deferoxamine on lead-induced cardiotoxicity in rats. Toxicol Ind Health. 2020 Aug 19:748233720947231. doi: 10.1177/0748233720947231. Epub ahead of print. PMID: 32812511.